<DOC>
	<DOCNO>NCT00447031</DOCNO>
	<brief_summary>Exudative age relate macular degeneration ( ARMD ) common cause blindness old population . It clear single therapy address multifactorial pathogenesis disease . Recently , study intravitreal anti-VEGF therapy pegaptanib bevacizumab show beneficial effect visual acuity treatment neovascular ARMD . However , problem intravitreal injection therapy must frequently administer prolonged unknown period time maintain benefit . Prolonged , frequent injection may associate additional safety risk , lack convenience high treatment cost . Intravitreal steroid injection anti-inflammatory property limit VEGF upregulation initiate inflammation know one pathogenesis cause recurrence treatment neovascular ARMD . The researcher hypothesize combine treatment intravitreal bevacizumab triamcinolone acetonide may decrease recurrence rate treatment obviate frequent intravitreal injection treatment neovascular ARMD . In study , researcher compare recurrence rate combine treatment intravitreal bevacizumab triamcinolone acetonide versus intravitreal bevacizumab alone treatment neovascular ARMD .</brief_summary>
	<brief_title>Combination Therapy Neovascular Age Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Neovascular ARMD confirm 90+ noncontact lens biomicroscopy , fluorescein angiography , ocular coherence tomography Intractable systemic hypertension Recent myocardial infarct within 6 month enrollment Recent cerebrovascular attack within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>age relate macular degeneration</keyword>
	<keyword>intravitreal bevacizumab</keyword>
	<keyword>intravitreal triamcinolone acetonide</keyword>
	<keyword>neovascular age relate macular degeneration</keyword>
</DOC>